Download Dear Sir/Madam - University of Michigan College of Pharmacy

Curriculum Vitae
Meihua Rose Feng
OFFICE
#B015A Pharmacy Building, 428 Church Street
College of Pharmacy, The University of Michigan,
Ann Arbor, MI 48109-0504
Telephone: (734) 615-5278 (office), 741-7582 (home)
Email: [email protected]
EDUCATION
1981
B.S., Pharmaceutical Sciences, China Pharmaceutical University, Nanjing China
1984
Ph.D., Biopharmaceutics, Mario Negri Institute, Milan Italy
PROFESSIONAL EXPERIENCE
10/2005 – present:
Adjunct Associate Professor, College of Pharmacy and College of
Engineering, The University of Michigan (UM). Senior consultant, UM
PK/PD Core facility.
12/2003 – 10/2005: Associate Research Fellow, Pfizer Global Research and Development,
Department of Pharmacokinetics, Pharmacodynamics, and Drug
Metabolism, Ann Arbor, MI. Supervised B.S., M.S., and Ph.D. scientists
and postdoctoral fellows.
08/1999 – 12/2003: Senior Research Associate and Senior Principle Investigator, Pfizer Global
Research and Development, Department of Pharmacokinetics,
Pharmacodynamics, and Drug Metabolism, Ann Arbor, MI. Supervised
B.S., M.S., and Ph.D. scientists and postdoctoral fellows.
04/1995 – 08/1999: Research Associate and Principle Investigator, Pfizer Global Research and
Development, Department of Pharmacokinetics, Pharmacodynamics, and
Drug Metabolism, Ann Arbor, MI. Supervised B.S., M.S., and Ph.D.
students/scientists.
08/1990 - 04/1995: Senior Research Scientist, Pfizer Global Research and Development,
Department of Pharmacokinetics, Pharmacodynamics, and Drug
Metabolism, Ann Arbor, MI. Supervised B.S., M.S., and Ph.D.
students/scientists.
09/1989 - 08/1990: Postdoctoral Fellow under the supervision of Professor John G. Wagner at
the University of Michigan, College of Pharmacy, Ann Arbor.
12/1984 - 09/1989: Assistant and Associate Professor at China Pharmaceutical University,
Nanjing, China.
07/1981 - 11/1984: Research Assistant under the supervision of Professor S. Garattini at the
Mario Negri Institute of Pharmacological Research, Milan Italy.
1
PROFESSIONAL HONORS
1989 – 1990: Postdoctoral scholarship, the University of Michigan, Ann Arbor
1981 – 1984: Graduate Student Scholarship, the Chinese government for graduate study in
Europe
SCIENTIFIC AND PROFESSIONAL ACTIVITIES AT PFIZER
Development of New Medicine
 IND, IB, NDA, MAA filing, IB preparation, and product registration:
o Pregabalin (Lyrica, CI-1008) and backups (CI-1045, PD 299685, etc.)
o Gabapentin (Neurontin, CI-945)
o Gabapentin and naproxen combination (CI-1032)
o Antiobesity project: Cobalt mesoporpherin (PD 160384)
o Selective N-methyl-D-aspartate receptor antagonists (CI-1041 and backups)
o Neuronal N-type calcium channel blockers for stroke
o Anti-Parkinson project
o RAS anti-cancer project
o Neurodegeneration project (amyloid aggregation inhibitors for Alzheimer disease)
(PD 118057, PD 189062, PD 202091, etc.)
o Anti-schizophrenia project
 CI-1007 and backups
 Igmesine (CI-1019)
 CI-1043 (PAGOCLONE)
 Mixed dopamine D2/serotonin 5-HT2A receptor antagonists
Professional Expertise and Research
 Conducted remarkable research with approximately 40 manuscripts published in peer reviewed
journals in areas of: (1) pharmacokinetics-pharmacodynamics (PK/PD) modeling and population
pharmacokinetics (POPPK), (2) interspecies scaling and human PK projection, (3) blood-brain
barrier (BBB) penetration and quantitative structure-BBB penetration relationship.
 Served as a consultant for young scientists at Pfizer in pharmaceutical sciences, produced
method sheets as guidance for research, and co-chaired Department discussion groups of PK/PD
modeling, human PK projection, and BBB penetration.
 Very familiar with NONMEM, WINNONLIN, and S-PLUS with several posters and
manuscripts published in population PK and/or PK/PD modeling in 1997 – 2007.
Journal Reviewer
 Journal of Pharmaceutical Research
 Journal of Pharmaceutical Sciences
 Molecular Pharmaceutics
 Xenobiotica
 Journal of Pharmacy and Pharmacology
 Journal Chirality
 Journal of Agricultural and Food Chemistry
Professional Affiliation
2


American Association of Pharmaceutical Scientists
American Society of Clinical Pharmacology and Therapeutics
TEACHING AND RESEARCH AT THE UNIVERSITY OF MICHIGAN:
Courses:
 Pharmacokinetics and Biopharmaceutics (Pharm 464/560)
 Advanced Pharmacokinetics (Pharm 760)
 Fundamentals of Drug Delivery Systems (Pharm 762)
 Population Pharmacokinetics (Pharm 761)
 Modern Pharmaceutical Engineering (ChE/PharmSci 519) – Invited lecture
 Applied Pharmacokinetics and Toxicokinetics (Chem520) – Invited lecture
 Biomedical Engineering (BME321) – Invited lectures
 Bioorganic Principles of Medicinal Chemistry (MC532) – Invited lectures
Research:
 Population Pharmacokinetics (POPPK) and PK/PD modeling of the following projects:
o Clinical PK of Amifostine and its active metabolite WR1065 in liver cancer
patients.
o Population pharmacokinetics and pharmacodynamics of mycophenolic acid in
Chinese adult liver transplant patients.
o Population pharmacokinetics of isoniazid and the effect of NAT2 polymorphism.
o Population pharmacokinetics of citalopram in Chinese population.
o Clinical PK of 6-, 8-, 10-Gingerols and 6-Shogaol and Conjugate Metabolites in
Healthy Human Subjects.
o POPPK and PK/PD Doxorubicin and Cyclophosphamide in breast cancer patients.
o POPPK and PK/PD of MRX-1024 in prevention of mucositis in patients receiving
radiation therapy with concurrent chemotherapy for locally advanced squamous
cell cancer of the head and neck.
o POPPK and PK/PD of Jinsenosides in Human.
 Interspecies scaling and human PK prediction: Evaluation of the interspecies scaling of
50 drugs is ongoing; invited to write a book chapter of “Interspecies Scaling and the
Prediction of Human Pharmacokinetics” for "Encyclopedia on Drug Metabolism and
Interactions".
 Nutrition Transporters in Cancer.
Dissertation Committee Member:
 Huibing Zhang, China Pharmaceutical University
 Wenlong Huang, China Pharmaceutical University
 Zheng Lu, the University of Michigan
 Nan Zheng, the University of Michigan
 YeaMin Huh, the University of Michigan
 Bing Chen, Shanghai Jiao Tong University
 Mengjie Li, China Pharmaceutical University
3
Postdoctor Fellow and/or Interns:
Emily Nolan
Galina Sheflyan
Sally Choe
Micha Levi
Jagon Parepally
Herisha Mandula
Alex Tungel
Seyi Oadeniyi
Bei Yang
Jerry Yu
Maria Posada
Yuhua Xie
ShuPei Wu
Xiaomei Chen
Grants:
 A grant from the University to organize the seminar series entitled " Prevalence and
Clinical Significance of Metabolic Drug-Drug Interactions and Genetics”. PI: Rose Feng,
07/2011 – 07/2012.
 A grant from the University to organize the seminar series entitled "Pharmacometrics and
Personalized Medicine in the 21st Century”. PI: Rose Feng, 07/2008 – 07/2010.
 Vesicare and Sanctura for the Treatment of Overactive Bladder. The major goal of this
project is to compare several therapies for the treatment for of bothersome urge urinary
incontinence in women. PI: Cathy Spino, Consultant: Rose Feng (5% effort).
 Development of an anti-norovirus Inhibitor (NIH grant submitted 05/2010), PI:
Christiane Wobus, Co-PI: Rose Feng (10% effort).
 Acoustically Activatable Chemotherapy Emulsions for Prostate Cancer Treatment” (NIH
grant submitted 06/2010). PI: Oliver Kripfgans, Co-PI: Rose Feng (5% effort).
 An Open Label, Time-To-Event Continuous Reassessment Method, Phase I/II Study of
the Mammalian Target of Rapamycin (mTOR) Inhibitor RAD001 in Combination with
Imatinib (Gleevec) in Patients with Chronic Phase Chronic Myeloid Leukemia (CML)
with Persistent Molecular Disease. PI: Moshe Talpaz, Co-I: Rose Feng, 15% effort for 2
years; (Clinical trial will start in 07/2010).
 A state-of-the-art development paradigm including advanced computational tools and
experimental approaches to optimizing oral drug delivery and insuring optimal oral drug
product efficacy; PI: Gordon Amidon; Co-Invest: Rose Feng; (NIH grant U01 submitted
05/2010).
 Inhibition of De-ubiquitinase activity for Cancer Therapy (NIH RFA grant submitted
06/2010), PI: Nick Donato, Co-PI: Rose Feng (5% effort).
 Development of individualized medication in immunosuppressive therapy in patients
following liver transplantation. PI: Rose Feng, submitted in 04/2011 for a grant for
Collaboration on Biomedical Technologies U-M and Shanghai Jiao Tong University. PI:
Rose Feng.
4

A grant from the University to organize the seminar series entitled "The Prevalence and
Clinical Significance of Metabolic Drug-Drug Interactions and Cytochrome P450
Polymorphisms”. PI: Rose Feng, 07/2011 – 07/2013.
INVITED PRESENTATIONS
1.
Interspecies scaling and human PK projection. Invited oral presentation at China
Pharmaceutical University, Nanjing, China, June 2001.
2.
Brain drug delivery - a pharmaceutical perspective. Invited oral presentation at 5th
International Conference of Cerebral Vascular Biology, June 2003 Amarillo, Texas.
3.
Pharmacokinetics in drug discovery and development. Invited oral presentation for
“Biopharmaceutics Short Course,” Nanjing, China, June 2004.
4.
Introduction to population pharmacokinetics. Invited oral presentation at College of
Pharmacy of Beijing University, Beijing, China, May 2006.
5.
Drug transporters and drug delivery. Invited oral presentation at Institute of Materia
Medica, Chinese Academy of Medical Sciences, Beijing, China, May 2006.
6.
Introduction to population pharmacokinetics. Invited oral presentation at China
Pharmaceutical University, Nanjing, China, May 2006.
7.
Introduction to population pharmacokinetics. Invited oral presentation at College of
Pharmacy of Shanghai JioaTong University, Shanghai, China, June 2006.
8.
Drug transporters and drug delivery. Invited oral presentation at 70th Anniversary
symposium of China Pharmaceutical University, Nanjing, China, November 2006.
9.
Introduction to population pharmacokinetics. Invited oral presentation at Cancer Center,
University of Michigan, Spring 2007, Ann Arbor.
10.
ADME and Pharmacokinetics in Drug Discovery/Development. American Association of
Pharmaceutical Scientists (AAPS) Webinar e-learning program, June 1, 2010,
11.
Pharmacokinetics/Pharmacodynamics in Drug Discovery & Development. University of
Michigan Engineering School fall 2009, a seminar for the ChemE 696 semianr series for
ChemE/PharmE/BME students.
12.
PK/PD Extrapolation from Animals to Humans, Invited oral presentation at Beijing
University, College of Pharmacy, May 2011.
13.
PK/PD Extrapolation from Animals to Humans, Invited oral presentation at Shanghai
Jiaotong University, College of Pharmacy, May 2011.
14.
PK/PD Extrapolation from Animals to Humans, Invited oral presentation at Zhejing
University, College of Pharmacy, May 2011. Introduction to Population
Pharmacokinetics, Invited oral presentation at Zhejing University, College of Pharmacy,
May 2011.
15.
Inter-subject variability and the development of population pharmacokinetics. Invited
oral presentation at East China University of Science and Technology, Shanghai China,
May 2012.
16.
ADME comparison of macro- and small-molecules. Invited oral presentation at East
China University of Science and Technology, Shanghai China, May 2012.
17.
Introduction to Population PK (POPPK) Modeling. Invited oral presentation at 2012 fall
CACO conference at San Francisco.
5
18.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
PUBLICATIONS
S. Caccia, M. R. Feng, and S. Garattini. Plasma concentrations of trazodone and 1 (3chlorophenol)-piperazine in man after single oral dose of trazodone. J Pharm
Pharmacol. 1982, 34:605-7.
M. R. Feng, S. Caccia, and S. Garattini. 1-m-Chlorophenylpiperazine is an active
metabolite common to the psychotropic drugs trazodone, etoperidone and mepiprazole. J
Pharm Pharmacol. 1982, 34(10):674-5.
S. Caccia and M. R. Feng. Pharmacokinetic studies with high performance liquid
chromatography of etoperidone, mepiprazone and their active metabolite m-chlorophenyl
piperazine. Chromatography and Mass Spectrometry in Biological Science. Frigerio, A.,
ed. 1983, 29:37-41.
M. R. Feng, A. Abbiato, E. Benfenati, and S. Caccia. Quantitative analysis of minaprine
and some of its metabolites with application to kinetic studies in rats. J Chromatogr.
1983, 25;259(1):141-9.
S. Caccia, A. Nortarnicola, M. R. Feng, and E. Benfenati. Identification and quantitation
of 1-arylpiperazines, metabolites resulting from side-chain cleavage of (4-substituted
aryl-1-piperazinyl)alkyl heterocyclic derivatives in rat plasma and brain. J Chromatogr.
1984, 20;283:211-21.
S. Caccia and M. R. Feng. Kinetics and distribution of the beta-adrenergic agonist
salbutamol in rat brain. J Pharm Pharmacol. 1984, 36(3):200-2.
S. Caccia, M.R. Feng, G. Guiso. Disposition of the psychotropic drugs buspirone, MJ13805 and piribedil, and of their common active metabolite 1-(2-pyrimidinyl)-piperazine
in the rat. Xenobiotica. 1985, 15(10):835-44.
S. Caccia, M. R. Feng, and R. Urso. Ionization constants and partition coefficients of 1arylpiperazine derivatives. J Pharm Pharmacol. 1985, 37(8):567-70.
M. R. Feng, L. Aarons, R. Urso and S. Caccia. Ionization constant and lipophilicity of 1aryl-piperazines investigated by reverse phase high performance liquid chromatography.
J Chromatogr. 1985, 333(1):191-4.
S. Caccia, M. R. Feng, S. Garattini, and A. Notarnicola. 1-aryl-piperazines as active
metabolites of drugs with an aryl-piperazine side chain. Biochem Pharmacol 1985,
34:393-5.
Z. Huang, M. R. Feng, S. Pen, and Y. Shi. Synthesis and activity determination of some
tetrahydroprotoberberine quaternary ammonium compounds. J China Pharm Univ. 1988,
4:249-52.
W. Huang, M. R. Feng and S. Pen. Lipophilicity and cardiovascular activity of some
berberine derivatives. J China Pharm Univ 1989, 4: 165-7.
M. R. Feng, W. Huang, X. Wong, J. Zhao, and Y. Shi. Hydrolysis kinetics and capacity
factor of dauricine esters. Chinese J Chromatogr. 1989, 6:329-31.
M. R. Feng. Structure-pharmacokinetics studies and drug design. Chinese J Pharm
Industry. 1989, 5:229-32.
M. R. Feng, Editor for Chinese Pharmacopeia, English edition, 1989.
M. R. Feng, M. Liebert, G. Wedemeyer, H. Grossman, W. Mancino, M. William, J.
Wagner. Effect of verapamil on the uptake and efflux of etoposide (VP16) in both
sensitive and resistant cancer cells. Sel Cancer Ther. 1991, 7(2):75-83.
M. R. Feng, P. Siersma, C. Strenkoski, and D. S. Wright. Sensitive high-performance
liquid chromatographic method for a dopamine receptor agonist, CI-1007, and its
6
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
metabolite PD 147693 in monkey plasma. J Chromatogr B Biomed Appl. 1995,
665(1):193-9.
J. Wright, D. Downing, M. R. Feng, R. Hayes, T. Heffner, R. Mackenzie, L. Meltzer, T.
Pugsley, and L. Wise. The identification, characterization, and pharmacological profile of
three metabolites of 1,2,3,6-tetrahydro-4-phenyl-1-[(3-phenylcyclohexen-1yl)methyl]pyridine, a dopamine autoreceptor agonist and potential antipsychotic agent. J
Med Chem. 1995, 38(26):5007-14.
M. R. Feng, A. Corbin, Y. Wang, C. Christoffersen, J. Wiley, C. Strenkoski, E. Tucker,
F. Ninteman, L. Meltzer, T. Heffner and D.S. Wright. Pharmacokinetics and
pharmacodynamics of an investigational antipsychotic agent, CI-1007, and a metabolite
PD 147693 in rats and monkeys. Pharm Res. 1997, 14(3):329-36.
M. R. Feng, J. Atherton, S. Knoll, C. Strenkoski, and D. S. Wright. Determination of two
CI-1007 sulfate metabolites in monkey plasma and urine. J Chromatogr B Biomed Sci
Appl. 1997, 693(1):159-66.
B. S. Guo, T. Van Nood, M. R. Feng, and D. S. Wright. Sample pooling to expedite
bioanalysis and pharmacokinetic research. J Pharm Biomed Anal. 1998, 16(5):837-46.
J. Sramek, M. Eldon, E. Posvar, M. R. Feng, S. Jhee, J. Hourani, A. Sedman, N. Cutler.
Initial safety, tolerability pharmacodynamics, and pharmacokinetics of CI-1007 in
patients with schizophrenia. Psychopharmacol Bull. 1998, 34(1):93-9.
M. R. Feng, D. Rossi, C. Strenkoski, A. Black, P. DeHart, M. Lovdahl, and William
McNally. Disposition of cobalt mesoporphyrin in mice, rat, monkey, and dog.
Xenobiotica. 1998, 28(4):413-26.
M. R. Feng, J. Loo, and J. Wright. Disposition of the antipsychotic CI-1007 in rat,
monkey, dog, and human CYP2D6 extensive metabolizers: species comparison and
allometric scaling. Drug Metab Dispos. 1998, 26(10):982-8.
K. Hoffman, D. Rossi, M. R. Feng. Pharmacokinetic profiling of Cobalt Mesoporphyrin
in rat plasma using atomic absorption spectroscopy. J Pharm Biomed Anal. 1999, 19(34):319-26.
L. Hu, T. Ryder, M. Rafferty, M. R. Feng, S.Lotarski, D. Rock, M. Sinz, S. Stoehr, C.
Taylor, M. Weber, G. Miljanich, E. Millerman, Y. Wang, B. Szoke. Synthesis of a series
of 4-benzyloxyaniline analogs as neuronal N-type calcium channel blockers with
improved anticonvulsant and analgesic properties. J. Med. Chem. 1999, 42(20), 4239-49.
M. R. Feng, X. Lou, R, Brown, and A. Hutchaleelaha. Allometric pharmacokinetic
scaling: Towards the prediction of human oral pharmacokinetics. Pharm Res. 2000,
17(4):410-8.
L. Hu, T. Ryder, M. Rafferty, M. R. Feng, S.Lotarski, D. Rock, S. Stoehr, C. Taylor, M.
Weber, G. Miljanich, E. Millerman, B. Szoke. Neuronal N-type calcium channel
blockers: a series of 4-piperidinylaniline analogs with analgesic activity. Drug Des
Discov. 2000, 17(1):85-93.
L. Hu, T. Ryder, M. Rafferty, Siebers, K.M., M. R. Feng, B. Kuo, S. Lotarski, G.
Miljanich, E. Millerman, B. Szoke, C.Taylor. The discovery of [1-(4-dimethylaminobenzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine, an
N-type Ca++ channel blocker with oral activity for analgesia. Bioorg Med Chem. 2000,
8(6):1203-12.
T. Ryder, L. Hu, M. Rafferty, C. Taylor, M. R. Feng, S.Lotarski, D. Rock, S. Stoehr, G.
Miljanich, E. Millerman, B. Szoke. Synthesis and biological evaluation of a series of 4-
7
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
aminopiperidine derivatives as N-type calcium channel antagonists. Med. Chem. Res.
2000, 10(1): 11-18.
M. R. Feng, D. Turluck, J. Burleigh, R. Lister, C. Fan, A. Middlebrook, C. Taylor, T. Su.
Brain microdialysis and PK/PD correlation of Pregabalin in rats. Eur J Drug Metab
Pharmacokinet. 2001, 26(1-2):123-8.
M. R. Feng. Assessment of BBB penetration: in silico, in vitro, in vivo. Curr Drug
Metab. 2002, 3(6):647-57.
RW Hurley, D. Chatterjea, M. R. Feng, C. P. Taylor, D. Hammond. Gabapentin and
pregabalin can interact synergistically with naproxen to produce antihyperalgesia.
Anesthesiology. 2002, 97(5):1263-73.
T. Z. Su, M. R. Feng, and M. L. Weber. Mediation of highly concentrative uptake of
Pregabalin by L-type amino acid transport in Chinese hamster ovary and Caco-2 cells. J
Pharmacol Exp Ther. 2005, 313(3):1406-15.
E. R. Nolan, M. R. Feng, J. R. Koup, J. Liu, D. Turluck, Y. Zhang, J. B. Paulissen, N. B.
Olivier, T. Miller, M. B. Bailie. A novel predictive pharmacokinetic/pharmacodynamic
model of repolarization prolongation derived from the effects of terfenadine, cisapride
and E-4031 in the conscious chronic av node-ablated, His bundle-paced dog. J
Pharmacol Toxicol Methods. 2006, 53(1):1-10.
H. Mandula, J. R. Parepally, M R. Feng, and Q. R. Smith. Role of site-specific binding
to plasma albumin in drug availability to brain. J Pharmacol Exp Ther. 2006, (2):667 –
675.
Z. Lu, M. R. Feng, D. P. Normolle, L. Chen, T. S. Lawrence, and D. E. Smith. Clinical
pharmacokinetics of Amifostine and its active metabolite WR1065 in liver cancer
patients. Clinical Cancer Research (in process).
S. M. Zick, Z. Djuric, M. T. Ruffin, A. J. Litzinger, D. P. Normolle, M. R. Feng, D. E.
Brenner. Pharmacokinetics of 6-, 8-, 10-Gingerols and 6-Shogaol and Conjugate
Metabolites in Healthy Human Subjects. Cancer Epidemiology, Biomarkers &
Prevention 2008 Aug;17(8):1930-6.
N. Zhang, B. Chen, M.R. Feng. Interspecies scaling of mycophenolic acid and
extrapolation from animals to humans. Drug Metab and Dispos, submitted in 2011.
B. Chen, M.R. Feng, T. Jiang, O. Adeniyi, Y. Xu, J. Sun, H. Chen. Population
Pharmacokinetics of Citalopram in Chinese Population and its usage in the
bioequivalence study. Journal of Clinical Pharmacy and Therapeutics, in process.
M.R. Feng, N. Zheng, X. Zhang, Y. Huh, J. Yu. Interspecies Scaling and the Prediction
of Human Pharmacokinetics. Book chapter for "Encyclopedia on Drug Metabolism and
Interactions". John Wiley & Sons, Inc, online version published in 02/2012 and the print
version in 08/2012 (http://onlinelibrary.wiley.com/book/10.1002/9780470921920 ).
Y. Huh, D.E. Smith and M.R. Feng. Interspecies Scaling and Prediction of Human
Clearance: Comparison of Small and Macromolecule Drugs. Xenobiotica, in
2011,41(11):972-987.
M. Feng, DE Smith, DP Normolle, JA Knol, CC Pan, E Ben-Josef, Z Lu, M.R. Feng, J.
Chen, W Ensminger, TS Lawrence. A Phase I Clinical and Pharmacology Study Using
Amifostine as a Radioprotector in Dose-escalated Whole Liver Radiation Therapy. Int J
Radiat Oncol Biol Phys. 2012 Mar 20.
8
44.
Y. Huh, S. M. Hynes, D. E. Smith, M. R. Feng. Importance of Peptide Transporter 2 on
the Cerebrospinal Fluid Efflux Kinetics of Glycylsarcosine Characterized by Nonlinear
Mixed Effects Modeling. Pharm Res. 2013 May;30(5):1423-34 .
45.
M. Li C. Xia G. Wang Y. Xie M.R. Feng. Population pharmacokinetics and
pharmacodynamics of Ginseng Rg1, Rb1, Rd and Re in Chinese myocardial ischemia
patients following intravenous infusion of “Shenmai”. European J Clinical
Pharamcology in process.
46.
B. Chen, N. Zheng, P. Zou, W. Yang, M. R. Feng. Interspecies Pharmacokinetic Scaling
of Mycophenolic Acid Using Nonlinear Mixed Effects Modeling. Xenobiotica 2012 in
process.
47. P. Zou, X. R. Liu,S. Wong, M. R. Feng, L.Bianca. Comparison of in vitro-in vivo
extrapolation of biliary clearance using an empirical scaling factor versus transport-based
scaling factors in sandwich cultured rat hepatocytes. J Pharm Sci. 2013
Aug;102(8):2837-50.
9
MEETING PRESENTATIONS
1.
M. R. Feng and S. Pen. Structure pharmacokinetics study of aryl-piperazines. Poster for
1988 Proceedings of Chinese Second Conference on Drug Metabolism.
2.
M. R. Feng, H. Zhang, and S. Pen. Structure-activity studies of antithrombotic drugs.
Poster for 1988 Proceedings of Chinese Second Conference on Cardiovascular Drugs.
3.
L. Xia and M. R. Feng. Synthesis and antihypertensive activity of 3,4 disubstituted
phenylethylamine derivatives. Poster for 1989 Annual Meeting of American Association of
Pharmaceutical Scientists (AAPS), (Abstract published in Pharm Res 1989, 9(Supl):s 44).
4.
M. R. Feng, and H. Zhang. Synthesis of 7-substituted isoquinolines as blood platelet
aggregation inhibitors. Poster for 1989 AAPS Annual Meeting (Abstract published in Pharm
Res 1989, 9(Supl):s 44).
5.
M. R. Feng, C. Strenkoski, T. Parker, and D.S. Wright. Oral absorption of PD 143188 in
rats and monkeys. Poster for 1993 AAPS Annual Meeting (Abstract published in Pharm Res
1993, 10(Supl), S-320).
6.
M. R. Feng, J. Hinton, K. Hoffman, T. Parker, and D. S. Wright. Pharmacokinetics and oral
bioavailability of CI-988 ester prodrugs in Wistar rats. Poster for 1993 AAPS Annual
Meeting (Abstract published in Pharm Res 1993, 10(Supl), S-346).
7.
M. R. Feng, S. Bezek, A. Gandhi, C. Strenkoski, J. Wright, T. Woolf, and D. S. Wright.
Pharmacokinetics and metabolism of CI-1007 and analogues in rats and in isolated rat
hepatocytes. Poster for 1993 AAPS Annual Meeting (Abstract published in Pharm Res 1994,
10(supl) S-347).
8.
J. Wright, D. Downing, M. R. Feng, T. Heffner, T. Pugsley, L. Wise, and D. S. Wright.
Study of the structure-metabolism relationship of analogues of CI-1007 (PD 143188), a
dopamine autoreceptor agonist and potential antipsychotic agent. Poster for 1994 Society for
Neuroscience Meeting.
9.
D. Downing, J. Wright, L. Wise, M. R. Feng, C. Strenkoski, T. Pugsley, T. Heffner. The
synthesis and identification of metabolites of CI-1007, a dopamine D2 autoreceptor agonist
and potential antipsychotic agent. Poster for 1994 Society for Neuroscience Meeting, New
Orleans, LA.
10.
J. Atherton, M. R. Feng, and D. S. Wright. Sensitive HPLC assays for CI-1007 and 8
metabolites in monkey kidney tissue and plasma. Poster for 1995 Parke-Davis Analytical
Symposium, Ann Arbor, MI.
11.
M. R. Feng, A. Corbin, Y. Wang, C. Christoffersen, C. Strenkoski, E. Tucker, T. Parker, J.
Wiley, F. Ninteman, T. Heffner, and D. S. Wright. Pharmacokinetics and pharmacodynamics
of a potential antipsychotic agent CI-1007 in rats and monkeys. Poster for 1995 AAPS
Annual Meeting (Abstract published in Pharm Research 1995, 9(supl), S-399).
12.
M. A. Eldon, B. A. Underwood, E. L. Posvar, M. R. Feng, D. S. Wright, and A. J. Sedman.
Safety, tolerance, and pharmacodynamics of CI-1007, a dopamine autoreceptor agonist, in
healthy subjects. Poster for 1997 Annual Meeting of American Society for Clinical
Pharmacology and Therapeutics (ASCPT), San Diego, CA.
13.
S. Knoll and M. R. Feng. Quantitation of CI-1007 and a metabolite PD 147693 in dog
plasma. Poster for 1997 Parke-Davis Analytical Symposium.
14.
M. R. Feng, R. Brown, B. Underwood, E.L. Posvar, and M.A. Eldon Pharmacokinetics of
CI-1007, and investigational antipsychotic drug, in cytochrome P450 2D6 extensive
metabolizers. Poster for 1998 ASCPT Annual Meeting, San Diego, CA. (Abstract published
in Clin. Pharmacol and Ther, 2: 185, 1998).
10
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
M. A. Eldon and M. R. Feng. Modeling the circadian secretion of prolactin: application to
pharmacodynamic assessment of a dopamine agonist drug. Poster for 1998 ASCPT Annual
Meeting, San Diego, CA. (Abstract published in Clin. Pharmacol and Ther, 2: 183, 1998).
J. Vora1, C. Lathia1, S. Przybranowski, J. Hollembaek, J. Blankley, D. Leonard, J.
Kaltenbronn, J. Sebolt-Leopold, M. R. Feng, W. Li, and W. Leopold. Application of neural
network in development of structure-pharmacokinetic relationships. Poster for 1998 AAPS
Annual Meeting.
M. R. Feng, D. Turluck, J. Burleigh, R. Lister, C. Fan, A. Middlebrook, M. Whittico, C.
Taylor, T. Su, W. McNally, D. Welty. Blood-brain barrier influx and efflux of a system L
substrate, Pregabalin, using brain microdialysis. Poster for 1999 Gordon Research
Conference. Tilton, NH.
L. M. King, M. R. Feng, M. A. Albassam, J. Wright, K. Baker, M. Sinz, L. Meltzer, G. E.
Macallum, and R. M. Walker. Characterization and effects of crystal deposits in renal cortex
after oral administration of CI-1007 in monkeys. Poster for 40th annual meeting for Society
of Toxicology, 1999 (Abstract published in The Toxicologist, 1999, 48(3):31).
L. Hu, T. Ryder, M. Rafferty, M. R. Feng, S. Lotarski, D. Rock, M. Sinz, S. J. Stoehr, C.
Taylor, M. Weber, G. Miljanich, E. Millerman, Y. Wang, B. Szoke. Discovery of a neuronal
N-type calcium channel blocker, (S)-2-amino-1-{4-[4-benzyloxy-phenyl)-(3-methyl-but-2enyl)-amino]-piperidin-1-yl}-4-methyl-pentan-1-one, with improved anticonvulsant and
analgesic properties. Poster for 219th National Meeting, American Chemical Society, San
Francisco, CA 2000.
L. Hu, T. Ryder, M. Rafferty, M. R. Feng, S. Lotarski, D. Rock, M. Sinz, S. J. Stoehr, C.
Taylor, M. Weber, G. Miljanich, E. Millerman, Y. Wang, B. Szoke. Neuronal N-type
calcium channel blocker: structure-activity relationship of a series of (S)-2-amino-1-{4-[4benzyloxy-phenyl)-(3-methyl-but-2-enyl)-amino]-piperidin-1-yl}-4-methyl-pentan-1-one
analogs. Poster for 219th National Meeting, American Chemical Society, San Francisco, CA
2000.
L. Hu, T. Ryder, M. Rafferty, M. R. Feng, S. Lotarski, D. Rock, S. J. Stoehr, C. Taylor, M.
Weber, G. Miljanich, E. Millerman, Y. Wang, B. Szoke. The discovery of [1-(4dimethylamino-benzyl)-piperidin-4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2enyl)-amine, an N-type Ca++ channel blocker with oral activity for analgesia. Poster for 27th
Medicinal Chemistry Symposium, Kansas City, 2000.
L. Hu, T. Ryder, M. Rafferty, M. R. Feng, S. Lotarski, D. Rock, S. J. Stoehr, C. Taylor, M.
Weber, G. Miljanich, E. Millerman, Y. Wang, B. Szoke. Synthesis and biological evaluation
of a series of 4-aminopiperidine derivatives as N-type calcium channel antagonists. Poster for
27th Medicinal Chemistry Symposium, Kansas City, 2000.
S. Lotarski, L. Hu, T. Ryder, M. Rafferty, M. R. Feng, B. Kuo, C. Taylor, M. Weber, G.
Miljanich, E. Millerman, B. Szoke. The discovery of [1-(4-dimethylamino-benzyl)-piperidin4-yl]-[4-(3,3-dimethyl-butyl)-phenyl]-(3-methyl-but-2-enyl)-amine, an N-type Ca+2 channel
blocker with oral activity for analgesia. Poster for 30th Annual Meeting of Society for
Neuroscience, New Orelans, La. 2000.
C.Taylor, L. Hu, T. Ryder, M. Rafferty, M. R. Feng, S. Lotarski, D. Rock, S. J. Stoehr, C.
Taylor, M. Weber, G. Miljanich, E. Millerman, Y. Wang, B. Szoke. Neuronal N-type
calcium channel blocker: structure-activity relationship of a series of (S)-2-amino-1-{4-[4benzyloxy-phenyl)-(3-methyl-but-2-enyl)-amino]-piperidin-1-yl}-4-methyl-pentan-1-one
11
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
analogs. Poster for 30th Annual Meeting of Society for Neuroscience, New Orelans, La.
2000.
G. Y. Sheflyan, M. R. Feng, B. P. Evens, D. Welty, T. Z. Su. Correlation between structural
factors of the compounds and their affinity to the neutral amino acid (system L) transport.
Poster for 2000 AAPS Annual Meeting, Indianapolis, IN.
G. Y. Sheflyan, M. R. Feng, H. Hallak, B. P. Evens. Comprehensive QSPKR modeling for
brain penetration of a series of basic drugs. Podium for 2000 AAPS Annual Meeting,
Indianapolis, IN.
U. Kale, M. R. Feng, H. Ando. A miniature closed-loop dissolution apparatus. Poster for
2000 Pfizer Analytical Symposium, Ann Arbor, MI.
L M. King, S C Groom, M. R. Feng, and R M Walker. Neuroendocrine effects of CI-1007 in
mice and rats. Poster for 40th Annual Meeting for Society of Toxicology, 2001.
M. R. Feng, A. El-Kattan, G. Y. Bernstein, B. P. Evens, H. Hallak. QSPKR modeling of
blood-brain barrier penetration for basic, acidic, and neutral drugs. Poster for 2001 AAPS
Annual meeting, Indianapolis, Denver, CO.
Ayman F. El-Kattan, M. R. Feng, Hussein Hallak, Eric M. Gifford. Prediction of the protein
bound fraction of acidic drugs using hydrogen bonding and calculated log P descriptors.
Poster for 2001 AAPS Annual Meeting, Indianapolis, Denver, CO.
M. R. Feng, W. Li, R. Lister, K. Berna, S. Ferreira, P. Knowlton, Scott Fountain. Brain
microdialysis and PK studies of Gabapentin and Naproxen in rats after single or coadministration. Poster for 2001 Pfizer CNS symposium, Ann Arbor, MI.
M. R. Feng, D. Ouellet, P. Knowlton, W. Li, K. Berna, S. Suzi Ferreira, S. Fountain.
Pharmacokinetic interaction of Gabapentin and Naproxen in rat and human. Poster for 2003
ASCPT Annual Meeting, Washington D.C. (Abstract published in Clin. Pharmacol & Ther,
2003, 2:50)
M. R. Feng, J. Koup, J. Liu, D. Turluck, Y. Zhang, S. Michael, E. R. Nolan, and M. B.
Bailie. PK/QT modeling of Terfenadine, Cisapride, and E-4031 in His paced dogs. 2004
PDM Department Symposium, Pfizer Ann Arbor.
M. R. Feng, S Choe, J. Atherton, H. Chen, D. Turluck, X.Yang, K. Szczap, I. Ionita, V.
Reddy, L. Zhang, M. Cherukury, A. Mutlib, J. Cook, P. Worboys. Retrospective analysis of
human PK projection for the CNS compound PD 343701. 2004 PDM Department
Symposium, Pfizer Ann Arbor, MI.
Q. R. Smith, J. Parepally, H. Mandula, X. Liu, M. R. Feng. Role of plasma protein binding
in drug uptake and equilibration in brain. Poster for 2004 Society for Neuroscience Annual
Meeting, San Francisco, CA.
J. Parepally, H. Mandula, X. Liu, M. R. Feng, and Q. R. Smith. Role of active efflux and
plasma protein binding in limiting brain access of NSAIDs. Poster for 2004 Society for
Neuroscience Annual Meeting, San Francisco, CA.
M. R. Feng, J. Mehran, B. Soldo, E. Nolan, M. Bailie, and P. Worboys. QT risk assessment
in preclinical models: in silico, in vitro, and in vivo. 2005 PDM Department Symposium,
Pfizer Ann Arbor, MI.
M. R. Feng, J. Koup, L. Radulovic, H. Bockbrader, P. Worboys. Pregabalin:
pharmacokinetics, pharmacodynamics, and interspecies scaling. 2005 FDA Science Forum,
Washington DC.
A. R. Pierce, M. R. Feng, K. Masuda, J. Nash, T. Moran, D. Schrier, and D. Falb.
Distribution, pharmacokinetics and excretion of [125]Iodine labeled BMP-7 (OP-1)
12
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
52.
following a single dose administration in lumbar IVD or knee joint of NZW rabbits. Poster
for 6th International Meeting on Bone Morphogenetic Proteins, Croatia, Nov. 2006.
Z. Lu, M. R. Feng, D. P. Normolle, L. Chen, T. S. Lawrence, and D. E. Smith. Clinical
pharmacokinetics of Amifostine and its active metabolite WR1065 in liver cancer patients.
Poster for 2007 AAPS Annual Meeting, San Diego, CA.
Population pharmacokinetics and pharmacodynamics of mycophenolic acid in Chinese adult
liver transplant patients. B. Chen, M. R. Feng, X. Zhang, W. Zhang, H. Chen, A. Tungol, W.
Cai. Poster for 2009 AAPS Annual Meeting, Los Angeles, CA.
Population pharmcokinetics of isoniazid and the effect of NAT2 polymorphism. B. Chen, M.
R. Feng, O. Adeniyi, M. Hutmacher, X. Cao, W. Cai, J. Li. Poster for 2009 AAPS Annual
Meeting, Los Angeles, CA.
Population pharmacokinetics of citalopram in Chinese population. B. Chen, M. R. Feng, T.
Jiang, O. Adeniyi, Y. Xu, J. Sun, H. Chen. Poster for 2009 AAPS Annual Meeting, Los
Angeles, CA.
Interspecies Pharmacokinetic Scaling of Mycophenolic Acid Using Nonlinear Mixed Effects
Modeling. N. Zheng, B. Chen, J. Yu, P. Zou, and M.R. Feng. Poster submitted for 2010
AAPS Annual Meeting, New Orleans, LS.
Prediction of human clearance: Comparison of small and macromolecule drugs. Y. Huh, J.
Yu, A. Tungol, and M.R. Feng. Poster submitted for 2010 AAPS Annual Meeting, New
Orleans, LS.
Interspecies Pharmacokinetic Scaling of Four Different Drugs Using Nonlinear Mixed
Effects Modeling. J. Yu, Y. Huh, N. Zheng, A. Tungol, and M. R. Feng. Poster submitted for
2010 AAPS Annual Meeting, New Orleans, LS.
Interspecies Scaling and Pharmacokinetics of WR-1065 in Animals and Humans Using
Nonlinear Mixed Effects Modeling. B. Yang, M. R. Feng, Z. Lu, and D. E. Smith. Poster for
2011 American Pharmacometrics Annual Meeting, San Diego, CA.
Interspecies Pharmacokinetic Scaling of Dasatinib - an Application of Nonlinear Mixed
Effects Modeling. S. Wu and M. R. Feng. Poster for 2011 American Pharmacometrics
Annual Meeting, San Diego, CA.
Simultaneous pharmacokinetic modeling of WR-1065 in blood and tissues using nonlinear
mixed effects modeling and extrapolation from rats to humans with body weight as a
covariate. M. R. Feng, Xiaomei Chen, Matt Hutchmatt, Zheng Lu, Bei Yang, and David E
Smith. Poster for 2012 American Society of Clinical Pharmacology and Therapeutics Annual
Meeting, Washington DC.
Nonelinear Mixed-effects Modeling of the Distribution Kinetics of PEPT2 substrate,
Glycylsarcosine, at the Blood-Cerebrospinal Fluid Barrier", Y. Huh, M. R. Feng, 2012
American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting,
Baltimore, March 2012, Washington DC.
Nonlinear Mixed-effects Modeling of the Interspecies Pharmacokinetic Scaling of Cefadroxil
after Oral and Intravenous Bolus Administration. Maria M. Posada, David Smith, and M.
Rose Feng. Poster for 2012 American Society of Clinical Pharmacology and Therapeutics
Annual Meeting, Washington DC.
“Nonlinear Mixed-effects Modeling of the Pharmacokinetics of PEPT2 substrate,
Glycylsarcosine, in blood, kidney and cerebrospinal fluid”. Yeamin Huh, David E Smith, and
M. Rose Feng. Poster for 2012 World Conference on pharmacometrics.
13
53. Interspecies Pharmacokinetic Scaling of Four Macromolecular Drugs Using Nonlinear
Mixed Effects Modeling. X. Chen, M. Li, D. E. Smith, M. Rose Feng. 2012 AAPS Annual
Meeting, Chicago, IL.
54. Population Pharmacokinetics and pharmacodynamics of Ginsenosides Rg1, Rb, Rd and Re in
Chinese myocardial ischemia patients following intravenous infusion of “Shenmai”.
MengjieLi, Yehua Xie, Chunhua Xia, Guangji Wang, M. Rose Feng. 2012 AAPS Annual
Meeting, Chicago, IL.
55. Prediction of clearance and volume of distribution in humans: comparison of small- and
macro-molecule drugs MengjieLi, Xiaomei Chen, M. Rose Feng. 2012 AAPS Annual
Meeting, Chicago, IL.
56. Yehua Xie, David E. Smith, Yongjun Hu, Hong Shen, Meihua R Feng. Semi-Mechanistic
Population Pharmacokinetic Modeling of Cefadroxil: An Example of PEPT2-Mediated Renal
Tubular Reabsorption. May 2013, ACoP annual meeting, FL, USA.
57. X Wang, B. Chen, W. Yang, M. R. Feng. Pharmacokinetic and sampling strategy for
mycophenolic acid in liver transplant patients. 2013 AAPS Annual Meeting, San Antonio TX
.
14